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Serologic  evidence  suggests  that  West  Nile  virus 
(WNV) is widely distributed in horses in southern Africa. 
However, because few neurologic cases have been report-
ed, endemic lineage 2 strains were postulated to be non-
pathogenic in horses. Recent evidence suggests that highly 
neuroinvasive lineage 2 strains exist in humans and mice. 
To determine whether neurologic cases are being missed 
in southern Africa, we tested 80 serum or brain specimens 
from horses with unexplained fever (n = 48) and/or neu-
rologic signs (n = 32) for WNV. From March 2007 through 
June 2008, using reverse transcription–PCR (RT-PCR) and 
immunoglobulin (Ig) M ELISA, we found WNV RNA or IgM 
in 7/32 horses with acute neurologic disease; 5 horses died 
or were euthanized. In 5/7 horses, no other pathogen was 
detected. DNA sequencing for all 5 RT-PCR–positive cases 
showed the virus belonged to lineage 2. WNV lineage 2 may 
cause neurologic disease in horses in southern Africa. 
W
est Nile virus (WNV), a mosquito-born flavivirus 
of  the  family  Flaviviridae,  is  widely  distributed 
throughout Africa, the Middle East, Asia, parts of Europe, 
Australia, North and South America, and the Caribbean. 
The WNV transmission cycle involves birds as vertebrate 
hosts and ornithophilic mosquitoes as maintenance vectors 
(1). Isolates of WNV fall into 2 major genetic lineages: lin-
eage 1 is found in North America, North Africa, Europe, 
and Australia; lineage 2 strains are endemic to southern 
Africa and Madagascar (2,3). Recently, additional lineages 
in central and eastern Europe (lineages 3 and 4) (4,5) and 
India (lineage 5) have been reported (6).
Humans and horses are incidental hosts for WNV (7). 
Although most infections are benign, ≈20% of infected per-
sons have fever, rash, arthralgia, and myalgia, and for ≈1% 
of  these,  severe  disease,  including  meningoencephalitis, 
encephalitis, and polio-like flaccid paralysis, may develop. 
Rare cases result in hepatitis, myocarditis, pancreatitis (8), 
and death (1). Signs in horses are ataxia, weakness, recum-
bency, and muscle fasciculation (9–11). Seroepidemiologic 
studies suggest that asymptomatic infections frequently oc-
cur in horses (12,13), but neurologic infections result in a 
high case-fatality rate (30%–40%) (14). In 2002 the largest 
outbreak of WNV encephalomyelitis in horses was record-
ed in the United States; 15,257 cases were reported from 40 
states (11). This outbreak was followed in 2003 by the larg-
est outbreak in humans in the Northern Hemisphere (9,832 
cases) (1). The number of cases among horses was greatly 
reduced after the introduction of an inactivated vaccine for 
animals (10,15,16).
In the Karoo, a semidesert region in South Africa, in 
1974, WNV caused one of the largest outbreaks ever re-
corded in humans, affecting tens of thousands of people. 
During  this  outbreak  thousands  of  persons  visited  their 
local clinicians; however, no cases of neurologic disease 
were reported. In the 1980s, an epizootic involving WNV 
and Sindbis virus occurred in the Witwatersrand area of 
the  Gauteng  Province  in  South  Africa;  this  epizootic   
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affected hundreds of persons (17). Since then, the number 
of confirmed human cases has been  ≈5–15 per year, al-
though only a proportion of cases are subjected to labora-
tory investigation. In South Africa, severe disease has been 
recognized, including fatal hepatitis and several nonfatal 
encephalitis cases in humans as well as deaths in ostrich 
chicks, a foal, and a dog (2,18). Recently, a lineage 2 strain 
was  isolated  from  encephalitic  birds  in  central  Europe, 
which suggests that lineage 2 strains can spread outside 
their known geographic range and may cause severe dis-
ease in birds in non–WNV-endemic countries (19).
A recent serologic survey of thoroughbred horses has 
confirmed that WNV is widely distributed throughout South 
Africa; 11% of yearlings seroconverted over 1 year and up 
to 75% of their dams had been exposed (13). This study 
led to the postulation that endemic lineage 2 WNV strains 
were not a cause of neuroinvasive disease in horses because 
none of these horses had shown any clinical signs. Three 
seronegative horses inoculated with a recent WNV lineage 
2 strain (SPU381/00) isolated from a person with benign 
disease did not develop clinical signs (13). However, the 
strain used in these experiments was subsequently shown 
to be of low neuroinvasiveness in mice, compared with cer-
tain other South African strains (20). Subclinical cases are 
also frequently reported in horses in the United States (12). 
Experimental infection of 12 horses with the highly neu-
roinvasive NY99 strain resulted in neuroinvasive disease 
in only 1 animal; the remaining animals all seroconverted, 
but clinical disease did not develop and virus could not be 
isolated from their organs (21).
Comparison  of  South  African  and  North  American 
strains of WNV has shown that differences in neuroinva-
siveness are associated with specific genotypes, not with 
lineage,  and  that  highly  neuroinvasive  strains  exist  in 
lineages  1  and  2  (20,22).  To  determine  whether  equine 
cases of WNV are being missed in South Africa, for 16 
months we investigated horses with pyrexia or unexplained   
neurologic signs.
Materials and Methods
Clinical Cases
From March 2007 through June 2008, serum and/or 
postmortem brain specimens were collected from horses 
in  South  Africa  with  acute  fever  or  neurologic  disease; 
cases  were  detected  by  passive  surveillance.  Specimens 
were sent to the Department of Medical Virology, Univer-
sity of Pretoria, by the main veterinary diagnostic facilities 
in  South  Africa  (Onderstepoort  Veterinary  Institute  and 
the University of Pretoria Faculty of Veterinary Science, 
Onderstepoort) and by a group of private equine veterinar-
ians from Gauteng and the Northern Cape provinces, who 
were invited to submit samples from horses with suspected 
cases. Specimens from horses with fatal and severe neu-
rologic cases mostly came from the University of Pretoria 
(Pathology Department, Faculty of Veterinary Sciences) 
and the Onderstepoort Veterinary Institute; most were from 
horses with neurologic signs for which no alternative diag-
noses were made. Specimens from horses with fever were 
collected by the private veterinarians around Gauteng from 
horses with less severe disease. Cases that resembled Afri-
can horse sickness, i.e., pulmonary or cardiac disease, were 
not included.
Reverse Transcription–PCR Screening  
and DNA Sequencing
RNA was extracted with an RNeasy kit (QIAGEN, 
Hilden,  Germany)  according  to  the  manufacturer’s  rec-
ommendations. A nested real-time reverse transcription–
PCR (RT-PCR) specific for the WNV NS5 gene that dis-
tinguishes between lineages 1 and 2 with WNV-specific 
FRET probes on the basis of dissociation curve analysis 
was used to screen specimens (23). A product of 214 bp 
could be seen on agarose gel. All positive RT-PCR prod-
ucts were confirmed by sequencing of the NS5 region (ge-
nome positions 9091–9191) and analyzed on an ABI 3130 
sequencer as recommended by the supplier (Applied Bio-
systems, Foster City, CA, USA). RT-PCR amplification 
and sequence analysis of a 255-bp region of the E-protein 
(genome positions 1402–1656) was conducted as described 
before (2,24).
Phylogenetic Analysis
Sequences  were  aligned  by  using  ClustalX  version 
1.83  (http://bips.u-strasbg.fr/fr/Documentation/ClustalX) 
with the multiple-sequence alignment option. Maximum-
likelihood  trees  were  generated  by  using  PHYML  (25). 
Bootstrap statistics for 1,000 replicates were calculated by 
neighbor-joining analysis with a maximum composite like-
lihood model and a gamma parameter of 2, using MEGA 
version 4 (26). Distances between sequences were calcu-
lated by using MEGA version 4 (26) with the P-distance 
analysis option.
Serologic Testing
Horse serum samples were tested for flavivirus-spe-
cific antibodies first by hemagglutination inhibition (HI) 
assay and next by a WNV-specific immunoglobulin (Ig) 
M-capture ELISA on HI-positive specimens as described 
in (27). IgM-positive specimens were confirmed by neu-
tralization assays as described below.
IgM-Capture ELISA
The IgM-capture ELISA was conducted as described 
in (28) with virus-specific modifications. In brief, 100 µL/
well of goat antihorse IgM µ-chain (Kirkegaard and Perry 
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Laboratories, Inc., Gaithersburg, MD, USA) diluted 1:500 
in phosphate-buffered saline (PBS) without magnesium and 
calcium, pH 7.4, was adsorbed onto ELISA plates (Max-
iSorp, Nunc, Denmark) overnight in a humidity chamber 
at 4°C. Plates were washed 3× with 0.1% Tween-PBS; the 
same washing procedure followed each subsequent stage 
of the assay. Plates were blocked with 200 µL/well of 10% 
skim milk (Merck, Darmstadt, Germany) in PBS and in-
cubated at 37°C for 1 h. After washing, duplicate volumes 
of 100 µL of each test and control serum diluted 1:400 in 
2% skim milk in PBS (diluting buffer) were added to wells 
in rows A–D:1–12 and to corresponding wells in rows E–
G:1–12 and incubated at 37°C for 1 h. After washing, 100 
µL/well WNV antigen and mock antigen, diluted 1:400 
in diluting buffer, was added to rows A–D:1–12 and E–
G:1–12, respectively. After incubation at 37°C for 1 h and 
washing, 100 µL/well of mouse anti-WNV antibody diluted 
1:1,000 was added to each well and incubated at 37°C for 1 
h. Production, inactivation, preservation, and safety testing 
of WNV antigen (strain H442/58), mock antigen, and hy-
perimmune mouse anti-H442/58 serum were conducted as 
described (29). After washing, 100 µL/well goat antimouse 
IgG (H + L chain) HRPO-conjugate (Zymed Laboratories, 
Inc, San Francisco, CA, USA) diluted 1:2,000 was added 
to each well and incubated at 37°C for 1 h. Plates were 
washed, and 100 µL/well ABTS (2,2′-azino diethyl-benzo-
thiazoline-sulfonic acid) peroxidase substrate (Kirkegaard 
and Perry Laboratories, Inc.) was added to each well and 
the plate was incubated in the dark for 30 min at room tem-
perature (22°–25°C). The stop reagent, 1% sodium dodecyl 
sulfate, was added, and optical densities (ODs) were mea-
sured at 405 nm. Specific activity of each serum sample 
(net OD) was calculated by subtracting the nonspecific OD 
in wells with mock antigen from the specific OD in wells 
with virus antigen. A threshold value for interpretation of 
results was determined as mean plus 3 standard deviations 
of duplicate net OD readings for negative control serum.
HI Assay 
The HI assay was conducted as described previously 
(27),  except  that  the  sucrose-acetone-extracted  H442/58 
strain of WNV derived from mouse brain tissue (produced 
as described for the IgM-capture ELISA above) was used 
as an antigen. A serum sample was considered seropositive 
if it had a titer >1.3, equivalent to a serum dilution >1:20.
Serum Neutralization Test
The serum microneutralization procedure using Afri-
can green monkey kidney (Vero cells) was conducted as 
described previously (30), except that the SPU 93/01 iso-
late of WNV recovered in southern Africa was used as a 
source of antigen. The titer was expressed as the reciprocal 
serum dilution that inhibited 100% of viral cytopathic ef-
fect. A serum sample was considered positive when it had 
a virus neutralization titer >1.0, equivalent to a serum dilu-
tion >1:10.
Tests for Differential Diagnoses
African horse sickness virus (AHSV), equine encepha-
losis virus (EEV), and equine herpesviruses (EHV) 1 and 
4 were identified by using viral culture and antigen detec-
tion assays and/or complement fixation tests (31) on serum 
samples and using RT-PCR to detect AHSV and EHV (32). 
Rabies virus infections were identified by fluorescent an-
tigen detection tests on brain tissue (33). Immunoperoxi-
dase staining for EEV, EHV, AHSV, and flavivirus was 
performed, according to the method adapted from (34), on 
histopathologic sections of brain, spinal cord, spleen, liver, 
and lung after postmortem investigations.
Virus Culture
All specimens were inoculated onto Vero cell mono-
layers (18 hours old) in 25 cm2 tissue culture flasks supple-
mented with Eagle Minimum Essential Medium contain-
ing 2% fetal bovine serum, 100 IU/mL penicillin, 100 μg/
mL streptomycin, and 1mg/mL l-glutamine (GIBCO BRL, 
Invitrogen, Carlsbad, CA, USA). Inoculated cultures were 
microscopically  observed  for  cytopathic  effects  for  10 
days.
Results
Screening of Specimens
A total of 80 serum or brain specimens from horses 
with unexplained fever (n = 48) and/or neurologic symp-
toms (n = 32) were tested for WNV over the 16-month 
period. Most specimens from horses with neurologic signs 
came  from  Onderstepoort  Veterinary  Institute  and  the 
Department of Medical Virology, University of Pretoria; 
horses were from across the country; the specimens from 
horses with fever were mostly from horses with less severe 
disease in Gauteng.
WNV infection was identified for 7 (21.8%) of 32 acute 
neurologic cases (Table 1). For 5 cases, acute WNV infec-
tion could be confirmed by the presence of RNA through 
RT-PCR (4 brain specimens, 1 serum sample) as well as 
virus  isolation  from  1  brain  specimen.  Two  HI-positive 
cases could be confirmed as probable recent WNV infec-
tions by IgM ELISA and WNV-specific antibodies, which 
were confirmed by neutralization assays. None of the hors-
es with fever had WNV, although EEV was isolated from 
several. Affected horses ranged from 4 months to 19 years 
and were thoroughbreds, Arabians, Lipizzaners, Welsh po-
nies, warmbloods, and mixed breeds. Cases were identified 
in Gauteng, the Northern Cape, and North-Western prov-
inces and occurred in April 2007 and from March through 
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June 2008. Of the 7 WNV-infected horses, 5 died or were 
euthanized for humane reasons (Table 2).
Co-infections
For 5 horses, 3 of which had fatal infections, no virus 
other than WNV was identified. Two horses that died (8 
months of age and 6 years of age) had co-infections with 
AHSV. For both horses, WNV was detected by RT-PCR 
in the brain and AHSV was detected in the spleen or lungs 
but not in the brain. The 6-year-old horse had documented 
records of up-to-date AHSV vaccinations. All cases were 
negative  by  immunoperoxidase  staining,  virus  isolation, 
and/or PCR for EHV and EEV.
Clinical Description of WNV
All confirmed WNV infections were identified in the 
group of horses with neurologic signs (Tables 1,2). Five 
horses with WNV died or had to be euthanized after be-
coming paralyzed. Signs included ataxia in all cases (7/7), 
weak hindlimbs and/or forelimbs and paresis (4/7), com-
plete paralysis (2/7), seizures (2/7), chewing (1/7), partial 
blindness (2/7), jaundice and/or hepatitis (2/7), and miosis 
of the pupils (1/7). One horse (HS101/08) (Table 2) was 
recumbent from quadriplegia and displayed limb paddling, 
teeth grinding, and muscle twitching; signs progressed over 
3 days to those similar to rabies, i.e., chewing fits, seizures, 
and coma before death, but fluorescent antigen detection 
results for rabies were negative. Fever was intermittent and 
not reported for all horses. The 2 WNV-infected horses that 
survived showed clinical signs for ≈21 days and had to be 
rested for several months, but each recovered fully.
Postmortem investigations were performed on 4 hors-
es (HS125/08, SAE 126/08, M123/08, and HS101/08). All 
4 had positive WNV results by real-time RT-PCR of brain 
tissue, and a WNV isolate was obtained from the brain of 
HS101/08. Virus isolation attempts on frozen specimens 
from the other 3 horses were not successful. AHSV was 
also isolated from the lungs and spleen of SAE126/08 and 
HS125/08.  Immunohistochemical  staining  of  organs,  to 
identify AHSV, EEV, and EHV, confirmed the presence 
of AHSV in SAE126/08, but results were negative for all 
other horses. Detailed postmortem findings for the 2 horses 
that had no complications (HS101/08 and M123/08) are 
shown in Table 2. Immunohistochemical staining for flavi-
viruses demonstrated antigen in the lumbar spinal cord and 
in some gray matter axons of HS101/08 (Figure 1).
Sequence Confirmation and Phylogenetic Analysis
The 5 specimens that were positive for WNV by RT-
PCR were subjected to sequence analysis and confirmed to 
be  WNV  by  BLAST  (www.ncbi.nlm.nih.gov/blast/Blast.
cgi) search analysis. Phylogenetic comparison of the 189-
bp NS5 gene region with representative sequences of all 
5 currently recognized WNV lineages confirmed that all 
strains clustered with lineage 2 (Figure 2) and were closely 
related to lineage 2 strains isolated from humans in South 
Africa.  The  horse  specimens  differed  by  0%–3%  nucle-
otides from southern African lineage 2 strains in the NS5 
region. Recent (2008) strains displayed the least variation 
from each other (0%–1.2%) and were most closely related 
to strains SPU116/89 and SA93/01, which had been isolated 
from a person with fatal hepatitis and nonfatal encephali-
tis, differing by 1.2% and 1.8%, respectively. Specimens 
from southern Africa had 1.2%–4.8% differences compared 
with the lineage 2 Hungary isolate of 2004. All lineage 2 
strains from southern Africa differed by 18.6%–19.2% from 
the Madagascar strain and by 19.2%–25.7% with lineage 1 
strains. Additional phylogenetic analysis of a more variable 
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Table 1. Viral diagnostic findings, West Nile virus–infected horses, South Africa* 
Case no. 
Date sample 
received Location Specimen Final diagnosis Results of tests for other viruses 
SAE12/07 2007 Apr 23  Johannesburg, Sandton, 
Gauteng 
Plasma WNV IgM+  AHSV–, EEV– 
SAE89/08 2008 Mar 3  Colesburg North Cape  Plasma WNV IgM+  AHSV–, EEV– 
HS101/08 2008 Apr 15  Tiegerpoort Pretoria, Gauteng Brain WNV PCR+, DNA 
sequencing L2, 
virus isolae WNV 
PCR+
Rabies–, AHSV–, EEV–, EHV–, 
flavivirus antigen in lumbar spinal 
cord section and in some gray matter 
axons (Figure 1) 
M123/08 2008 May 8  Midrand, Gauteng  Brain WNV PCR+, DNA 
sequencing L2 
AHSV–, EEV–, EHV– 
HS125/08 2008 May 26  Pretoria, Hammans-kraal, 
Gauteng 
Brain WNV PCR+, DNA 
sequencing L2 
AHSV from spleen PCR+; AHSV 
from lung IHC+, lymph node IHC–, 
liver IHC– 
SAE126/08 2008 Mar 7  Midrand, Gauteng  Brain WNV PCR+, DNA 
sequencing L2 
AHSV RT-PCR+, AHSV type 7; IHC 
EEV–, AHSV+, AHSV IHC+ (lung 
liver, heart)
SAE134/09 2008 Jul 18  Potchef-stroom, North-
Western Province 
Serum WNV PCR+, DNA 
sequencing L2 
AHSV–, EEV–, EHV-1 weak sero+ 
*WNV, West Nile virus, Ig, immunoglobuliln; AHSV, African horse sickness virus; EEV, equine encephalosis virus; EHV, equine herpesvirus; L2, lineage 
2; –, negative; +, positive; RT-PCR, reverse transcription–PCR; IHC, immunohistochemistry. Lineage 2 West Nile Virus in Horses, South Africa
region of the E-protein was performed on the 2008 isolate 
obtained from the brain of HS101/08 (Figure 3). HS101/08 
had 0.07%–2% differences in the E-protein region com-
pared with all other southern Africa lineage 2 strains and 
was the closest to SPU116/89; it differed by 6.9% from the 
prototype Uganda strain (B956), differed by 17.3% from a 
strain from Madagascar, and 23% from NY385/99 (lineage 
1). The 2004 Hungary lineage 2 strains differed by only 
1.6% from the southern Africa strains, which suggests that 
the Hungary strains may have originated from southern Af-
rica. On the amino acid level, all southern Africa lineage 2 
strains’ E-protein regions were identical to each other and to 
the Hungary strain but differed by 7% from the Madagascar 
strain and by 23% from the lineage 1 NY385/99 strain.
Discussion
Lineage 2 WNV is known to be endemic to southern 
Africa; however, few cases of WNV disease have been re-
ported in recent years and the role of lineage 2 as a human 
and horse pathogen has been disputed (3,13). Our previous 
investigations of the pathogenicity of lineage 2 strains in 
humans and mice have indicated the existence of lineage 2 
strains that are highly pathogenic and neuroinvasive in mice 
(2,20). WNV is rarely considered in a differential diagnosis 
for neurologic disease of humans or horses in southern Af-
rica. In the Northern Hemisphere, horses are highly suscep-
tible and develop severe WNV disease and thus have been 
used as sentinels for human cases (35). Most indigenous 
birds in southern Africa do not display disease despite a 
high seroprevalence for WNV infection (17), which sug-
gests that genetic resistance may exist in local birds.
We investigated 80 cases of unexplained disease in hors-
es compatible with WNV clinical signs. It can be expected 
that not all cases were identified but rather that samples from 
only economically valuable horses were sent in for laboratory 
investigation when unexplained neurologic signs and fevers 
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Table 2. Clinical findings, West Nile virus–infected horses, South Africa* 
Case no.  Age Clinical findings  Outcome Postmortem findings  Histopathologic findings 
SAE12/07 5 y  Neurologic signs, 
hind and fore limb 
ataxia, pupil miosis, 
head held to left 
Survived
SAE89/08 1 y  Neurologic signs, 
hind and forelimb 
ataxia, fever, 
complete paralysis, 
anorexia, hepatitis 
Died
(euthanized
after week of 
fluid therapy)
Postmortem not done 
HS101/08 8 y  Neurologic signs, 
severe ataxia 
especially hind limb, 
seizures and 
chewing, froth from 
mouth, fever, 
recumbency, 
paralysis  
Died Marked generalized 
subcutaneous edema 
involving trunk and proximal 
forelimbs, edema (periaortic, 
coronary grooves, neck, and 
hind quarters), partial 
pulmonary collapse, foam-
filled trachea, mild 
serosanguinous hydrothorax, 
moderate hydropericardium, 
subpleural petechiae and 
ecchymoses, epicardial 
grooves and at bases of the 
mitral valves
Lesions in gray matter and meninges of 
lumbar spinal cord (pericentral canal 
gliosis, edema, gray matter gliosis with 
occasional neuronal degeneration or 
death), mild perivascular cuffing with 
mononuclear cells and scattered 
neutrophils, moderate vascular 
congestion, occasional perivascular 
petechiae, mild leptomeningitis (mostly 
round cells) and occasional mild spinal 
ganglioneuritis, segmental mural necrosis 
of the dural blood vessels and neutrophil 
invasion, less-marked lesions in rest of 
spinal cord and white matter of midbrain 
M123/08 4 mo  Fever, neurologic 
signs, paralysis 
(Schiff-Sherington 
sign), rectal 
prolapse
Died Severe perirenal and 
intermuscular edema, severe 
diffuse interlobular lung 
edema and mild serous 
hydropericardium  
Marked white matter lesions in peripheral 
lateral and ventromedial spinal cord white 
matter, mild perivascular round cell 
cuffing in midbrain, patchy spongiosis and 
gliosis in brain and cerebellum white 
matter
HS125/08 8 mo  Neurologic signs, 
ataxia, mild colic, 
swollen head and 
neck
Died (shot by 
owner) 
Severe lung edema and 
congestion, moderate serous 
hydropericardium, 
intermuscular edema  
Subtle lesions on brain and cerebellum 
sections (e.g., gliosis and spongiosis in 
white matter and vascular leukostasis) 
SAE126/08 6 y  Neurologic signs, 
head hanging, sick 
for week  
Died
suddenly 
Spinal cord lesions 
SAE134/09 19 y  Neurologic signs, 
partial blindness, 
hyperexcitability, 
seizures
Survived
*AHSV, African horse sickness virus; IHC, immunohistochemistry. RESEARCH
were noted by the resident veterinarian. For 7 horses, WNV 
could be confirmed by RT-PCR and virus isolation (5) or as 
the probable cause of signs due to the presence of IgM con-
firmed by neutralization assays, suggesting a recent WNV 
infection. All 7 horses had substantial neurologic signs. The 
fact that 5 cases were fatal suggests that up to 7 (21.8%) of 
32 cases of undetermined neurologic disease investigated 
in horses in South Africa over 16 months were caused by 
WNV. The high mortality rate (5 [71%] of 7 horses) and the 
clinical signs correlated with findings of neurologic disease 
in horses in the Northern Hemisphere.
Samples from 5 horses were positive by nested real-
time RT-PCR (4 brain tissue specimens and 1 serum sam-
ple), and 2 were IgM positive. These findings indicate that 
these were useful diagnostic and surveillance tools.
Sequencing of cDNA confirmed that all WNV infec-
tions were caused by lineage 2 and were closely related 
to lineage 2 strains previously isolated from human case-
patients in South Africa. The NS5 gene regions of the 2008 
strains were most closely related to each other and to recent 
human isolates. The WNV SPU93/01 isolate was recovered 
from  an  immunocompetent  adult  who  was  hospitalized 
with encephalitis in Johannesburg in 2001; the SPU116/89 
isolate was recovered from the liver of a human patient 
with fatal hepatitis. Analysis of horse isolate HS101/08 in-
dicated that the 2008 strains were unique in the E-protein 
region and most closely related to SPU116/89, followed by 
SPU93/01. Each of these strains is highly neuroinvasive in 
mice (18,20).
All cases were identified in late summer to autumn, 
timing that coincides with AHSV and EEV outbreaks in 
South Africa (36,37). The extent of these cases caused by 
concurrent and cocirculating viruses may contribute to the 
underrecognition of WNV cases in horses in southern Af-
rica. Some of the WNV cases reported here were submit-
ted as suspected AHSV and EEV infections. AHSV is an 
insect-borne orbivirus that causes a noncontagious disease 
of equids and is associated with high death rates in sub-
Saharan Africa. African horse sickness occurs in 4 forms: 
horse sickness fever (mild), cardiac (>50% mortality rate), 
mixed (75% mortality rate), and pulmonary (95% mortality 
rate). Signs of the cardiac form include subcutaneous ede-
ma, particularly of the head, neck, chest, and supraorbital 
fossae. The pulmonary form is peracute and may develop 
so rapidly that an animal can die without previous signs 
of illness. It is characterized by depression, fever, respi-
ratory distress, severe dyspnea and coughing spasms, and 
severe sweating; terminally, quantities of frothy fluid may 
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Figure 1. Histopathologic section of 2 lumbar spine gray matter 
dendrites that stained immunohistochemically positive with flavivirus 
antiserum on postmortem tissue of horse HS101/08. Magnification 
×1,000.
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Figure 2. Maximum-likelihood comparison of the partial NS5 gene 
of West Nile virus (WNV) strains identified in horses in South Africa 
in  2008  with  representative  sequences  of  other  WNV  lineages. 
Bootstrap statistics are shown on the branches; only values >70% 
are  included.  Scale  bar  indicates  0.07  nt  changes.  Japanese 
encephalitis virus (JEV) was used as an outgroup. Black diamonds, 
WNV  strains  identified  in  horses  in  South Africa  in  the  present 
study; white diamonds, WNV strains isolated from humans in South 
Africa in previous years. WNV strains and accession numbers and 
origin: HS123_08, FJ464376, South Africa; HS125_08, FJ464377, 
South  Africa;  HS101_08,  FJ464378,  South  Africa;  SAE126_08, 
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Russia; LEIV-Vlg00–27924, AY278442, Russia; LEIV-Krnd88–190, 
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NY385_99, DQ211652 NY, USA; NY99-eqhs, AF260967 NY, USA; 
NY99-flamingo382–99, AF196835 NY, USA; TYP9376 NY385_99, 
AY848697  NY,  USA;  WNV  TX  2002  02,  DQ164206  TX,  USA; 
TM171_03,  AY371271,  Mexico;  Mex03,  AY660002,  Mexico;  TX 
2002-HC,  DQ176637 TX,  USA;  WNV804994,  DQ256376,  India; 
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be discharged from the nares and periods of recumbency 
may occur (37). Annual vaccination with a live attenuat-
ed polyvalent AHSV vaccine provides protection against 
most of the 9 serotypes, although vaccine failures have 
been reported and outbreaks continue to occur. Vaccina-
tion complicates diagnosis by serologic testing, and virus 
may be isolated from horses after vaccination (38). EEV is 
a closely related orbivirus also widespread in southern Af-
rica; it may cause fever, abortion, and neurologic involve-
ment (39). Outbreaks of both occur annually and are as-
sociated with unusually high rainfall and increased vector 
(Culicoides midges) populations (40), which will also fa-
vor an increase in Culex mosquitoes, which transmit WNV. 
The 2007–2008 summer and late autumn seasons in South 
Africa were marked by unusually high rainfall, and the 
numbers of AHSV and EEV cases were also high (www.
africanhorsesickness.co.za). Clinical signs of AHSV do not 
resemble those of WNV, and neurologic signs are not char-
acteristic; but in the absence of laboratory testing, horses 
that die of unexplained causes may be dismissed as having 
been infected with AHSV. The identification of 2 AHSV–
WNV co-infections in this study is therefore not surprising. 
In both cases, veterinarians and owners noted neurologic 
signs, which are not typical of AHSV. These co-infections 
may increase the disease severity for each virus and should 
be taken into consideration in areas where both diseases are 
endemic. In most (5/7) WNV cases identified in this study, 
no other pathogens were identified. All identified horses 
with WNV infection had neurologic involvement, which 
could be used to distinguish WNV–AHSV co-infections 
from conventional AHSV infections. None of the identified 
horses with EEV had neurologic signs, although EEV virus 
was isolated from several horses with fever.
Our findings should raise awareness that WNV lineage 
2 can cause neurologic disease in both horses and humans 
in southern Africa. In the absence of bird deaths, detection 
of cases in horses may serve as an early warning system for 
WNV outbreaks among humans.
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